Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation at the H.C. Wainwright Global Life Sciences Conference. The Company will be featured as a presenting company. The conference will be held on a virtual platform from March 9-10, 2021.
As part of the Company's presentation, Dr. Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, will provide an overview of the Company's business and product candidates.
If you are an institutional investor, and would like to listen to the Company's presentation, please click on the following link to register for the conference: www.hcwevents.com/globalconference.
The conference will feature over 400 corporate presentations and panels both live and on-demand. Dr. Sandler's presentation is accessible using a webcast link.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the H.C. Wainwright Global Life Sciences Investment Conference provides the Company with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally. It also allows us to further establish Hemogenyx Pharmaceuticals as a leader in the field of the development of medicines for treatment of blood and autoimmune diseases. "
https://www.share-talk.com/dr-vladislav-sandler-ceo-co-founder-of-hemogenyx-pharmaceuticals-hemo-l-interview/
As part of the Company's presentation, Dr. Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, will provide an overview of the Company's business and product candidates.
If you are an institutional investor, and would like to listen to the Company's presentation, please click on the following link to register for the conference: www.hcwevents.com/globalconference.
The conference will feature over 400 corporate presentations and panels both live and on-demand. Dr. Sandler's presentation is accessible using a webcast link.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the H.C. Wainwright Global Life Sciences Investment Conference provides the Company with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally. It also allows us to further establish Hemogenyx Pharmaceuticals as a leader in the field of the development of medicines for treatment of blood and autoimmune diseases. "
https://www.share-talk.com/dr-vladislav-sandler-ceo-co-founder-of-hemogenyx-pharmaceuticals-hemo-l-interview/
Show Notes
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation at the H.C. Wainwright Global Life Sciences Conference. The Company will be featured as a presenting company. The conference will be held on a virtual platform from March 9-10, 2021.
As part of the Company's presentation, Dr. Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, will provide an overview of the Company's business and product candidates.
If you are an institutional investor, and would like to listen to the Company's presentation, please click on the following link to register for the conference: www.hcwevents.com/globalconference.
The conference will feature over 400 corporate presentations and panels both live and on-demand. Dr. Sandler's presentation is accessible using a webcast link.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the H.C. Wainwright Global Life Sciences Investment Conference provides the Company with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally. It also allows us to further establish Hemogenyx Pharmaceuticals as a leader in the field of the development of medicines for treatment of blood and autoimmune diseases. "
https://www.share-talk.com/dr-vladislav-sandler-ceo-co-founder-of-hemogenyx-pharmaceuticals-hemo-l-interview/
Listen On
Also Listen
-
Zak Mir talks to Eric Benz, CEO and David Craven, an investor at Vaultz Capital.
Zak Mir talks to Eric Benz, CEO and David Craven, an investor at Vaultz Capital. -
Zak Mir talks to Nick Thurlow, Executive Chairman of Hamak Gold
Zak Mir talks to Nick Thurlow, Executive Chairman, Hamak Gold, following the ann -
Zak Mir talks to Malcolm Palle, Executive Chairman of Coinsilium Group Limited
Coinsilium's Strategic Approach to Bitcoin Treasury Management Zak Mir talks to -
Zak Mir talks to Howard White, Interim Chairman of Hydrogen Utopia International PLC
Zak Mir talks to Howard White, Interim Chairman, Hydrogen Utopia, as the pioneer